News

Umeåföretag tar nästa steg mot ett nytt läkemedel

PRESSMEDDELANDE 2019-03-06 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier har visat mycket goda resultat och potential [...]

Lipum to NASDAQ

On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with [...]

We develop an anti-inflammatory drug with first-in-class potential

We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Lipum also address the treatment of Juvenile Iodiopathic Artrithis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

SHORT FACTS:

An autoimmune disease is caused by the individuals immune response to its own body.

Autoimmune diseases are for example RA, IBD, psoriasis, diabetes mellitus type 1, Graves disease, inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis.

Rheumatoid Artrithis

  • more common among woman
  • increased occurence for elderly
  • 0.2-1.3% have the diagnosis worldwide
  • USD 19.7 bn market (2014, Nature Reviews)

Juvenile Iodiopathic Artrithis

  • onset before 16 years of age
  • 80,000 affected both in EU and the US